ORIGINAL RESEARCH
Benzimidazole derivative as antitumor drug against experimentally induced lung carcinoma
1 National Medical Research Center of Oncology, Rostov-on-Don, Russia
2 Rostov State Medical University, Rostov-on-Don, Russia
3 Research Institute for Physical and Organic Chemistry of Southern Federal University, Rostov-on-Don, Russia
Correspondence should be addressed: Ekaterina A. Lukbanova
Azovskaya, 163, 346783, Azov; ur.xednay@ajaksramas.aytak
Funding: synthesis of the tested compound was supported by the Russian Ministry of Science and Higher Education under the state assignment for the Southern Federal University, 2020, Project FENW-2020-0031 (0852-2020-0031). In vivo experiments were part of the state assignment Study of antitumor activity of pharmacological substances in vivo and in vitro (121031100253-3).
Author contributions: Komarova EF proposed the design, conducted the experiment and wrote the draft version of the manuscript; Zhukovskaya ON synthesized the tested compound and edited the manuscript; Lukbanova EA conducted the experiment and contributed to writing the manuscript; Yengibaryan MA edited the manuscript; Vashenko LN proposed the concept and design for the study, edited the manuscript; Kharagezov DA contributed to writing the manuscript; Pozdnyakova VV performed statistical analysis; Ushakova ND proposed the concept and design for the study; Shatova YuS prepared the list of references and edited the manuscript; Przhedetsky YuV performed technical editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of National Medical Research Center for Oncology (Protocol № 18 dated September 10, 2015); the experiment complied with the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes.